Relapse rates in moderately severe chronic psoriasis treated with cyclosporin A
SUMMARY Seventeen patients with chronic psoriasis were given cyclosporin A (CsA) 5 mg/kg per day. Twelve patients cleared within 3 months and their relapse rate, 41% at 6 months, was not significantly different from that previously reported with dithranol or PUVA. This pilot study also suggests that...
Gespeichert in:
| Veröffentlicht in: | British journal of dermatology (1951) 1989-07, Vol.121 (1), p.71-74 |
|---|---|
| Hauptverfasser: | , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 74 |
|---|---|
| container_issue | 1 |
| container_start_page | 71 |
| container_title | British journal of dermatology (1951) |
| container_volume | 121 |
| creator | HIGGINS, E. MUNRO, C. MARKS, J. FRIEDMANN, P.S. SHUSTER, S. |
| description | SUMMARY
Seventeen patients with chronic psoriasis were given cyclosporin A (CsA) 5 mg/kg per day. Twelve patients cleared within 3 months and their relapse rate, 41% at 6 months, was not significantly different from that previously reported with dithranol or PUVA. This pilot study also suggests that continuing CsA for up to 4 weeks after clinical clearance confers no advantage with regard to relapse. Significant adverse effects on renal function and blood pressure did not occur. |
| doi_str_mv | 10.1111/j.1365-2133.1989.tb01402.x |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_79132703</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>79132703</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3501-f43370619ebd6ed7c77ad0037ec6a78c8538b4c4aee34ae8b88bf81ced6382163</originalsourceid><addsrcrecordid>eNqVkNFu0zAUhq2JaZTBIyBZCO0uwY4T25nExdigDE2dBExcWo5zorlLk-CTbu3b46hR7_GFLev_fvvoI-QDZymP69M65UIWScaFSHmpy3SsGM9Zlu5OyOIYvSILxphKWCnFa_IGcc0YF6xgZ-QsU4UqC70g9z-htQMCDXYEpL6jm76G6dLuKcIzBKDuMfSdd3TAPniLHukYIBI1ffHjI3V71_Y4xKyjV2_JaWNbhHfzeU4evn39ff09ubtf3l5f3SVOFIwnTS6EYpKXUNUSauWUsjVjQoGTVmmnC6Gr3OUWQMRNV1pXjeYOail0xqU4JxeHd4fQ_90Cjmbj0UHb2g76LRpVcpEpJiJ4eQBd6BEDNGYIfmPD3nBmJptmbSZlZlJmJptmtml2sfx-_mVbbaA-Vmd9Mf845xadbZtgO-fxiMlSZnGEiH0-YC--hf1_DGC-_LhRPPaTQ9_jCLtj34YnI5VQhfmzWpql1qtfN_nKMPEP_YOg4g</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>79132703</pqid></control><display><type>article</type><title>Relapse rates in moderately severe chronic psoriasis treated with cyclosporin A</title><source>MEDLINE</source><source>Access via Wiley Online Library</source><creator>HIGGINS, E. ; MUNRO, C. ; MARKS, J. ; FRIEDMANN, P.S. ; SHUSTER, S.</creator><creatorcontrib>HIGGINS, E. ; MUNRO, C. ; MARKS, J. ; FRIEDMANN, P.S. ; SHUSTER, S.</creatorcontrib><description>SUMMARY
Seventeen patients with chronic psoriasis were given cyclosporin A (CsA) 5 mg/kg per day. Twelve patients cleared within 3 months and their relapse rate, 41% at 6 months, was not significantly different from that previously reported with dithranol or PUVA. This pilot study also suggests that continuing CsA for up to 4 weeks after clinical clearance confers no advantage with regard to relapse. Significant adverse effects on renal function and blood pressure did not occur.</description><identifier>ISSN: 0007-0963</identifier><identifier>EISSN: 1365-2133</identifier><identifier>DOI: 10.1111/j.1365-2133.1989.tb01402.x</identifier><identifier>PMID: 2757958</identifier><identifier>CODEN: BJDEAZ</identifier><language>eng</language><publisher>Oxford, UK: Blackwell Publishing Ltd</publisher><subject>Adult ; Biological and medical sciences ; Chronic Disease ; Cyclosporins - therapeutic use ; Female ; Humans ; Male ; Medical sciences ; Middle Aged ; Pharmacology. Drug treatments ; Psoriasis - drug therapy ; Recurrence ; Skin, nail, hair, dermoskeleton</subject><ispartof>British journal of dermatology (1951), 1989-07, Vol.121 (1), p.71-74</ispartof><rights>1990 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c3501-f43370619ebd6ed7c77ad0037ec6a78c8538b4c4aee34ae8b88bf81ced6382163</citedby><cites>FETCH-LOGICAL-c3501-f43370619ebd6ed7c77ad0037ec6a78c8538b4c4aee34ae8b88bf81ced6382163</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1111%2Fj.1365-2133.1989.tb01402.x$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1111%2Fj.1365-2133.1989.tb01402.x$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>315,781,785,1418,27929,27930,45579,45580</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=6962033$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/2757958$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>HIGGINS, E.</creatorcontrib><creatorcontrib>MUNRO, C.</creatorcontrib><creatorcontrib>MARKS, J.</creatorcontrib><creatorcontrib>FRIEDMANN, P.S.</creatorcontrib><creatorcontrib>SHUSTER, S.</creatorcontrib><title>Relapse rates in moderately severe chronic psoriasis treated with cyclosporin A</title><title>British journal of dermatology (1951)</title><addtitle>Br J Dermatol</addtitle><description>SUMMARY
Seventeen patients with chronic psoriasis were given cyclosporin A (CsA) 5 mg/kg per day. Twelve patients cleared within 3 months and their relapse rate, 41% at 6 months, was not significantly different from that previously reported with dithranol or PUVA. This pilot study also suggests that continuing CsA for up to 4 weeks after clinical clearance confers no advantage with regard to relapse. Significant adverse effects on renal function and blood pressure did not occur.</description><subject>Adult</subject><subject>Biological and medical sciences</subject><subject>Chronic Disease</subject><subject>Cyclosporins - therapeutic use</subject><subject>Female</subject><subject>Humans</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Pharmacology. Drug treatments</subject><subject>Psoriasis - drug therapy</subject><subject>Recurrence</subject><subject>Skin, nail, hair, dermoskeleton</subject><issn>0007-0963</issn><issn>1365-2133</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1989</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqVkNFu0zAUhq2JaZTBIyBZCO0uwY4T25nExdigDE2dBExcWo5zorlLk-CTbu3b46hR7_GFLev_fvvoI-QDZymP69M65UIWScaFSHmpy3SsGM9Zlu5OyOIYvSILxphKWCnFa_IGcc0YF6xgZ-QsU4UqC70g9z-htQMCDXYEpL6jm76G6dLuKcIzBKDuMfSdd3TAPniLHukYIBI1ffHjI3V71_Y4xKyjV2_JaWNbhHfzeU4evn39ff09ubtf3l5f3SVOFIwnTS6EYpKXUNUSauWUsjVjQoGTVmmnC6Gr3OUWQMRNV1pXjeYOail0xqU4JxeHd4fQ_90Cjmbj0UHb2g76LRpVcpEpJiJ4eQBd6BEDNGYIfmPD3nBmJptmbSZlZlJmJptmtml2sfx-_mVbbaA-Vmd9Mf845xadbZtgO-fxiMlSZnGEiH0-YC--hf1_DGC-_LhRPPaTQ9_jCLtj34YnI5VQhfmzWpql1qtfN_nKMPEP_YOg4g</recordid><startdate>198907</startdate><enddate>198907</enddate><creator>HIGGINS, E.</creator><creator>MUNRO, C.</creator><creator>MARKS, J.</creator><creator>FRIEDMANN, P.S.</creator><creator>SHUSTER, S.</creator><general>Blackwell Publishing Ltd</general><general>Blackwell</general><scope>BSCLL</scope><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>198907</creationdate><title>Relapse rates in moderately severe chronic psoriasis treated with cyclosporin A</title><author>HIGGINS, E. ; MUNRO, C. ; MARKS, J. ; FRIEDMANN, P.S. ; SHUSTER, S.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3501-f43370619ebd6ed7c77ad0037ec6a78c8538b4c4aee34ae8b88bf81ced6382163</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1989</creationdate><topic>Adult</topic><topic>Biological and medical sciences</topic><topic>Chronic Disease</topic><topic>Cyclosporins - therapeutic use</topic><topic>Female</topic><topic>Humans</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Pharmacology. Drug treatments</topic><topic>Psoriasis - drug therapy</topic><topic>Recurrence</topic><topic>Skin, nail, hair, dermoskeleton</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>HIGGINS, E.</creatorcontrib><creatorcontrib>MUNRO, C.</creatorcontrib><creatorcontrib>MARKS, J.</creatorcontrib><creatorcontrib>FRIEDMANN, P.S.</creatorcontrib><creatorcontrib>SHUSTER, S.</creatorcontrib><collection>Istex</collection><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>British journal of dermatology (1951)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>HIGGINS, E.</au><au>MUNRO, C.</au><au>MARKS, J.</au><au>FRIEDMANN, P.S.</au><au>SHUSTER, S.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Relapse rates in moderately severe chronic psoriasis treated with cyclosporin A</atitle><jtitle>British journal of dermatology (1951)</jtitle><addtitle>Br J Dermatol</addtitle><date>1989-07</date><risdate>1989</risdate><volume>121</volume><issue>1</issue><spage>71</spage><epage>74</epage><pages>71-74</pages><issn>0007-0963</issn><eissn>1365-2133</eissn><coden>BJDEAZ</coden><abstract>SUMMARY
Seventeen patients with chronic psoriasis were given cyclosporin A (CsA) 5 mg/kg per day. Twelve patients cleared within 3 months and their relapse rate, 41% at 6 months, was not significantly different from that previously reported with dithranol or PUVA. This pilot study also suggests that continuing CsA for up to 4 weeks after clinical clearance confers no advantage with regard to relapse. Significant adverse effects on renal function and blood pressure did not occur.</abstract><cop>Oxford, UK</cop><pub>Blackwell Publishing Ltd</pub><pmid>2757958</pmid><doi>10.1111/j.1365-2133.1989.tb01402.x</doi><tpages>4</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0007-0963 |
| ispartof | British journal of dermatology (1951), 1989-07, Vol.121 (1), p.71-74 |
| issn | 0007-0963 1365-2133 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_79132703 |
| source | MEDLINE; Access via Wiley Online Library |
| subjects | Adult Biological and medical sciences Chronic Disease Cyclosporins - therapeutic use Female Humans Male Medical sciences Middle Aged Pharmacology. Drug treatments Psoriasis - drug therapy Recurrence Skin, nail, hair, dermoskeleton |
| title | Relapse rates in moderately severe chronic psoriasis treated with cyclosporin A |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-14T07%3A15%3A44IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Relapse%20rates%20in%20moderately%20severe%20chronic%20psoriasis%20treated%20with%20cyclosporin%20A&rft.jtitle=British%20journal%20of%20dermatology%20(1951)&rft.au=HIGGINS,%20E.&rft.date=1989-07&rft.volume=121&rft.issue=1&rft.spage=71&rft.epage=74&rft.pages=71-74&rft.issn=0007-0963&rft.eissn=1365-2133&rft.coden=BJDEAZ&rft_id=info:doi/10.1111/j.1365-2133.1989.tb01402.x&rft_dat=%3Cproquest_cross%3E79132703%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=79132703&rft_id=info:pmid/2757958&rfr_iscdi=true |